{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["7(1)"],"submitter":["Harada T"],"pubmed_abstract":["<h4>Objective</h4>To study the impact of estetrol (E4), a novel native estrogen with selective tissue activity, on endometriosis-associated pelvic pain (EAPP) and global impressions of endometriosis pain.<h4>Design</h4>Multicenter, randomized, open-label, active-controlled study; 88 eligible Japanese participants with endometriosis were randomized to either the E4 15 mg/drospirenone (DRSP) 3 mg group or the ethinyl estradiol (EE) 20 μg/DRSP 3 mg group. Participants received assigned treatment for 12 weeks.<h4>Subjects</h4>Japanese patients aged ≥20 and <50 years diagnosed with endometriosis. Eligibility required an EAPP score ≥40 mm on the visual analogue scale (VAS).<h4>Intervention</h4>Participants were randomized 1:1 to E4/DRSP or EE/DRSP groups.<h4>Main outcome measures</h4>Change in E"],"journal":["F&S reports"],"pagination":["38-45"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12905615"],"repository":["biostudies-literature"],"pubmed_title":["Impact of estetrol and drospirenone combination therapy on alleviation of the pelvic pain of endometriosis: a randomized control trial."],"pmcid":["PMC12905615"],"pubmed_authors":["Harada T","Meguro K","Kobayashi T","Nogami M","Iizuka M","Manda C","Hirayama M"],"additional_accession":[]},"is_claimable":false,"name":"Impact of estetrol and drospirenone combination therapy on alleviation of the pelvic pain of endometriosis: a randomized control trial.","description":"<h4>Objective</h4>To study the impact of estetrol (E4), a novel native estrogen with selective tissue activity, on endometriosis-associated pelvic pain (EAPP) and global impressions of endometriosis pain.<h4>Design</h4>Multicenter, randomized, open-label, active-controlled study; 88 eligible Japanese participants with endometriosis were randomized to either the E4 15 mg/drospirenone (DRSP) 3 mg group or the ethinyl estradiol (EE) 20 μg/DRSP 3 mg group. Participants received assigned treatment for 12 weeks.<h4>Subjects</h4>Japanese patients aged ≥20 and <50 years diagnosed with endometriosis. Eligibility required an EAPP score ≥40 mm on the visual analogue scale (VAS).<h4>Intervention</h4>Participants were randomized 1:1 to E4/DRSP or EE/DRSP groups.<h4>Main outcome measures</h4>Change in E","dates":{"release":"2026-01-01T00:00:00Z","publication":"2026 Feb","modification":"2026-07-15T16:35:38.367Z","creation":"2026-07-07T03:08:39.476Z"},"accession":"S-EPMC12905615","cross_references":{"pubmed":["41694262"],"doi":["10.1016/j.xfre.2025.12.002"]}}